BACKGROUND Transcatheter left atrial appendage (LAA) occlusion is an alternative strategy for stroke prevention in
Thrombus formation on the device is a possible finding during follow-up after LAA closure. Most studies report an incidence of device-associated thrombus close to 3% to 6%, although a higher rate was reported in a small study (12) . The clinical significance of thrombus formation on the device is poorly known, and whether it is associated with more frequent occurrence of ischemic strokes is debated (10, 13, 14) . Moreover, consensus on appropriate antithrombotic regimens after LAA closure remains an issue. The aim of this study was to evaluate, in daily practice, clinical outcomes in patients using the 2 main LAA closure systems, differences in antithrombotic management at discharge from hospital, and the incidence, predictors, and prognosis of thrombus formation on the device after LAA occlusion. A Bleeding Academic Research Consortium type 3 or more hemorrhage was considered a major hemorrhage (17) . A device-related thrombus was defined as the detection of a thrombus adherent to the luminal (left atrial) side of the device by TEE or CT scan.
Major adverse events were defined as all-cause death, ischemic strokes or TIAs, major hemorrhages, and device-related thrombus occurring during follow-up. Dr. Piot has received a research contract and hospitality from Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Manuscript received November 2, 2017; revised manuscript received December 27, 2017, accepted January 26, 2018. score, were less likely to be treated with OAC or antiplatelet therapy at discharge, and were less likely to undergo LAA imaging during follow-up. Among patients with a nitinol plug device, those with the newer version had a similar CHA 2 DS 2 -VASc score, but they were less likely to be treated with OAC at discharge and were less likely to undergo LAA imaging during follow-up.
OUTCOMES. Mean follow-up was 13 AE 13 months, during which 339 (72.3%) patients underwent LAA imaging at least once to detect thrombus on the device using TEE (n ¼ 263) or a CT scan (n ¼ 76). There were 98 major adverse events (26 thrombi on device, 19 ischemic strokes, 2 TIAs, 18 major hemorrhages, 33 deaths) recorded in 89 patients ( Table 2) . No intracranial bleeding was documented after device Values are mean AE SD or n (%). Percentages calculated from available data. *In patients with implanted device.
AF ¼ atrial fibrillation; APT ¼ antiplatelet therapy; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, prior stoke or transient ischemic attack or thromboembolism, vascular disease, age 65 to 74 years, and female sex; HAS-BLED ¼ hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio, elderly (age <65 years), drug or alcohol use; LAA ¼ left atrial appendage; LV ¼ left ventricular; OAC ¼ oral anticoagulation.
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A P R I L 1 0 , 2 0 1 8 : 1 5 2 8 -3 6 implantation. Mean time to first LAA imaging was 2.8 AE 2.5 months, and mean time to thrombus detection on the device was 3.1 AE 2.6 months. The rate of thrombus on the device was 8.3% in patients with LAA imaging using TEE and 5.3% with LAA imaging using a CT scan (p ¼ 0.52).
The overall incidence of thrombus on the device was 5.5% in patients treated with a nitinol cage device, 8.2% with the older version of the nitinol plug, and 25.0% with the newer version (overall p ¼ 0.001).
One patient had a stroke leading to atrial imaging and a diagnosis of thrombus on the LAA occluder device. Table 3) .
On multivariable analysis, older age and history of stroke were predictors of thrombus formation on the device, whereas DAPT and OAC at discharge were associated with a lower risk of thrombus on device (Table 4) . 
DISCUSSION
We report the outcomes in a relatively large, multicenter, retrospective study of consecutive patients with AF who were treated with LAA closure, not restricted by the use of a single device. In this large analysis, industry had no role in the design, analysis, or reporting of the study. We found that the initial The antithrombotic regimen at discharge differed between the patients treated with the 2 devices, a finding that may reflect historical trials and reports with each device (2, 8, 10, 18) . We found no difference in clinical outcomes between the 2 occlusion devices, consistent with a previous registry that compared outcomes with nitinol cage and nitinol plug devices, in a far smaller number of patients (19) . However, we report higher rates of mortality, ischemic strokes, and major hemorrhages than in other studies (2, 4, 19) .
This finding may be explained by the older age, higher thromboembolic risk, and higher bleeding profile in our very high-risk patients: approximately 40% had a prior stroke, a rate markedly higher than in the EWOLUTION registry (6), and 90% had a prior bleeding episode. Our study reflects results obtained in a "real-life" practice for all patients treated with LAA occlusion at a nationwide level, who overall may be sicker than those patients included in a randomized trial (with no contraindication to OAC) or in other declarative registries. Underdiagnosis of events in other studies is also possible.
A recent systematic review reported a mean incidence of 3.4% for device-associated thrombus after LAA occlusion (13), whereas we found a higher overall rate. We found no significant difference in rates of thrombus when using TEE or CT scans for LAA imaging. The incidence of thrombus formation on devices varies widely in current registries (12, 20) , and this may be explained by the different sample sizes, lack of consensus on the definition of deviceassociated thrombus, or reporting bias related to different imaging methods and their frequency during follow-up. The 7.2% rate of device-related thrombus in our study is still within this range and is similar to rates in other large registries, although it is more likely to reflect the true incidence of thrombus on the device. Our result for thrombus incidence rate with the nitinol cage device (5.5%) is relatively consistent with rates observed in the PRO-TECT AF (2) and ASAP (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology) studies (18) , which were 4.2% and 4%, respectively. We found a higher rate of thrombus formation with a cardiac plug device, but the higher risk did not reach significance in multivariable analysis. We report an 11.0% rate of thrombus related to the nitinol plug devices in the first year, a rate that is higher than the 2% to 4% reported in other studies (10, 21, 22) . The incidence of device-related thrombus with nitinol plug devices thus varies in published reports and may be higher when considering other registries (20).
The rate of device-related thrombus in our study may have been underestimated, considering the number of patients who did not undergo LAA imaging Values are mean AE SD or n (%). *Analysis restricted to patients with LAA imaging during follow-up.
Abbreviations as in Table 1 .
Fauchier et al. Limited data are available on risk factors for thrombus formation on the device (13, 14) . We found that older age and prior ischemic stroke were predictive of thrombus on the device. DAPT and OAC at discharge were associated with a lower risk of thrombus formation, and this finding may have clinical implications over longer-term follow-up. The prognosis associated with thrombus formation on the device is poorly known. In a cohort of 339 patients undergoing nitinol plug implantation, it was suggested that device-associated thrombus may have a low thromboembolic risk (14) . By contrast, stroke, peripheral embolism, or cardiac death occurred at a rate of 3.4 per 100 patient-year follow-up in 93
patients undergoing LAA closure with the nitinol cage device (23) . Considering all types of devices, a 7.3% rate of ischemic stroke or TIA has been reported in patients with device-related thrombus (13) . In our study, using the 2 devices most commonly used for LAA occlusion, we found a yearly rate of 4.0%
for ischemic stroke, a little lower than what would be expected for this study group (24) but higher than that in other studies of LAA closure (2, 4, 6, 10, 14, 18, 19) . Importantly, we report that thrombus on the device was an independent factor strongly associated with strokes and TIA during follow-up. Causality between device-related thrombus and strokes cannot be retrospectively proven, but a direct relationship is plausible. However, patients with LAA closure have the propensity for other sources of emboli, and vascular disease was unsurprisingly also independently associated with a higher risk of stroke during subsequent follow-up.
Care should be exercised in the interpretation of data on the post-implantation regimen and the risk for subsequent device-related thrombus, given that the post-implantation regimen was not randomized, as in all recent studies on antithrombotic management after LAA occlusion (21, 25) . However, we found that DAPT at discharge was associated with a lower risk of thrombus formation on the device. This result concurs with previously suggested adequacy and better effectiveness of DAPT over OAC therapy after LAA closure. In the ASAP study (18) , patients with contraindications to OAC were treated with DAPT for 6 months, followed by aspirin alone, and a devicerelated thrombus rate of 4% was reported. This rate is similar to the 4.2% rate of nitinol cage-associated thrombus in the PROTECT AF trial, in which patients were treated with warfarin for 45 days, followed by DAPT for 6 months (2). In a single-center prospective cohort, DAPT administered for 6 weeks following LAA closure was associated with less frequent device-related thrombus (1.7%) compared with OAC at discharge (15.8%), regardless of the type of device (26) . Although these results appear to favor DAPT at discharge after LAA occlusion, generalization cannot be firmly recommended. First, nitinol cage and nitinol plug devices may have different thrombogenicity profiles and endothelialization processes (27) , and different antithrombotic management may The curves are representative of being event-free for ischemic strokes and transient ischemic attacks, with and without thrombus on the device, after left atrial appendage occlusion. Time zero is time at first post-procedure left atrial appendage imaging. The curves demonstrate a higher risk for ischemic strokes or transient ischemic attacks in the patients with a diagnosis of device-associated thrombus after left atrial appendage occlusion. The mean follow-up time was 13 AE 13 months.
CI ¼ confidence interval; HR ¼ hazard ratio.
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